person · Reporting owner

ORONSKY ARNOLD L

Disclosed activity across 9 companies

Tapewire entity: 146229
SEC CIK: 0001207833

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
APPLIED GENETIC TECHNOLOGIES CORPAGTC · Entity 121949	Director	April 24, 2017	April 26, 2017
DYNAVAX TECHNOLOGIES CORPDVAX · Entity 66930	Director	May 28, 2020	May 29, 2020
KalVista Pharmaceuticals, Inc.KALV · Entity 39180	Director	October 01, 2020	October 02, 2020
PMV Pharmaceuticals, Inc.PMVP · Entity 7062	Director · 10% owner	September 25, 2020	October 02, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

APPLIED GENETIC TECHNOLOGIES CORP

Report date April 24, 2017 · Filed April 26, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
CommonSEC Table I · non-derivative	IndirectBy Partnership	1,404,515	Reported balance After 2017-04-24 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2017-04-24 · Other · Acquired 3,559 · Balance 1,404,515 F1: Represents cashless exercise of a warrant by InterWest Partners VIII, LP ("IW8"). 7,917 shares of common stock were withheld by the issuer at the market price of $6.58 per share to fund the cashless exercise of 11,476 warrants. F4: Shares are owned by IW8. The General Partner of IW8 is InterWest Management Partners VIII, LLC ("IMP8"). The Reporting Person is a Managing Director of IMP8, shares voting and investment power with the other Managing Directors of IMP8, and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
CommonSEC Table I · non-derivative	IndirectBy Partnership	40,181	Reported balance After 2017-04-24 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2017-04-24 · Other · Acquired 101 · Balance 40,181 F2: Represents cashless exercise of a warrant by InterWest Investors Q VIII, LP ("IIQ8"). 227 shares of common stock were withheld by the issuer at the market price of $6.58 per share to fund the cashless exercise of 328 warrants. F5: Shares are owned by IIQ8. The General Partner of IW8 is IMP8. The Reporting Person is a Managing Director of IMP8, shares voting and investment power with the other Managing Directors of IMP8, and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
CommonSEC Table I · non-derivative	IndirectBy Partnership	11,208	Reported balance After 2017-04-24 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2017-04-24 · Other · Acquired 28 · Balance 11,208 F3: Represents cashless exercise of a warrant by InterWest Investors VIII, LP ("II8"). 63 shares of common stock were withheld by the issuer at the market price of $6.58 per share to fund the cashless exercise of 91 warrants. F6: Shares are owned by II8. The General Partner of IW8 is IMP8. The Reporting Person is a Managing Director of IMP8, shares voting and investment power with the other Managing Directors of IMP8, and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Warrant to buy CommonSEC Table II · derivative / convertible security · Conversion / exercise price $4.54 · Expires 2017-05-02	IndirectBy Partnership	0	Reported balance After 2017-04-24 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-04-24 · Other · Disposed 11,476 · Balance 0 F4: Shares are owned by IW8. The General Partner of IW8 is InterWest Management Partners VIII, LLC ("IMP8"). The Reporting Person is a Managing Director of IMP8, shares voting and investment power with the other Managing Directors of IMP8, and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Warrant to buy CommonSEC Table II · derivative / convertible security · Conversion / exercise price $4.54 · Expires 2017-05-02	IndirectBy Partnership	0	Reported balance After 2017-04-24 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2017-04-24 · Other · Disposed 328 · Balance 0 F5: Shares are owned by IIQ8. The General Partner of IW8 is IMP8. The Reporting Person is a Managing Director of IMP8, shares voting and investment power with the other Managing Directors of IMP8, and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Warrant to buy CommonSEC Table II · derivative / convertible security · Conversion / exercise price $4.54 · Expires 2017-05-02	IndirectBy Partnership	0	Reported balance After 2017-04-24 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2017-04-24 · Other · Disposed 91 · Balance 0 F6: Shares are owned by II8. The General Partner of IW8 is IMP8. The Reporting Person is a Managing Director of IMP8, shares voting and investment power with the other Managing Directors of IMP8, and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Represents cashless exercise of a warrant by InterWest Partners VIII, LP ("IW8"). 7,917 shares of common stock were withheld by the issuer at the market price of $6.58 per share to fund the cashless exercise of 11,476 warrants.

F2: Represents cashless exercise of a warrant by InterWest Investors Q VIII, LP ("IIQ8"). 227 shares of common stock were withheld by the issuer at the market price of $6.58 per share to fund the cashless exercise of 328 warrants.

F3: Represents cashless exercise of a warrant by InterWest Investors VIII, LP ("II8"). 63 shares of common stock were withheld by the issuer at the market price of $6.58 per share to fund the cashless exercise of 91 warrants.

F4: Shares are owned by IW8. The General Partner of IW8 is InterWest Management Partners VIII, LLC ("IMP8"). The Reporting Person is a Managing Director of IMP8, shares voting and investment power with the other Managing Directors of IMP8, and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

F5: Shares are owned by IIQ8. The General Partner of IW8 is IMP8. The Reporting Person is a Managing Director of IMP8, shares voting and investment power with the other Managing Directors of IMP8, and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

F6: Shares are owned by II8. The General Partner of IW8 is IMP8. The Reporting Person is a Managing Director of IMP8, shares voting and investment power with the other Managing Directors of IMP8, and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

DYNAVAX TECHNOLOGIES CORP

Report date May 28, 2020 · Filed May 29, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.84 · Expires 2027-05-27	Direct	25,000	Reported balance After 2020-05-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-05-28 · Grant · Acquired 25,000 · Balance 25,000 F2: Not applicable. F1: This option vests fully on May 28, 2021, on the one year anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: This option vests fully on May 28, 2021, on the one year anniversary of the grant date.

F2: Not applicable.

KalVista Pharmaceuticals, Inc.

Report date October 01, 2020 · Filed October 02, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.88 · Expires 2030-09-30	Direct	7,000	Reported balance After 2020-10-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-10-01 · Grant · Acquired 7,000 · Balance 7,000 F1: The option vests over a 12 month period: 1/12th on November 1, 2020, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests over a 12 month period: 1/12th on November 1, 2020, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date.

PMV Pharmaceuticals, Inc.

Report date September 25, 2020 · Filed October 02, 2020 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	6,469,911	Last balance in matching sequence After 2020-09-29 transaction · row 5 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 5 source rows Row 1 · 2020-09-25 · Purchase · Acquired 55,555 · Balance 55,555 F1: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Row 2 · 2020-09-29 · Conversion · Acquired 1,620,101 · Balance 1,675,656 F2: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Row 3 · 2020-09-29 · Conversion · Acquired 3,488,398 · Balance 5,164,054 F2: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Row 4 · 2020-09-29 · Conversion · Acquired 1,040,654 · Balance 6,204,708 F2: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Row 5 · 2020-09-29 · Conversion · Acquired 265,203 · Balance 6,469,911 F2: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
Series Seed Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-29 transaction · row 6 Amendment: may correct only part of an earlier disclosure. 1 source row Row 6 · 2020-09-29 · Conversion · Disposed 1,620,101 · Balance 0 F2: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-29 transaction · row 7 Amendment: may correct only part of an earlier disclosure. 1 source row Row 7 · 2020-09-29 · Conversion · Disposed 3,488,398 · Balance 0 F2: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-29 transaction · row 8 Amendment: may correct only part of an earlier disclosure. 1 source row Row 8 · 2020-09-29 · Conversion · Disposed 1,040,654 · Balance 0 F2: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-29 transaction · row 9 Amendment: may correct only part of an earlier disclosure. 1 source row Row 9 · 2020-09-29 · Conversion · Disposed 265,203 · Balance 0 F2: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

F2: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date.

Past disclosures · reporting ended (5)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AVEDRO INC

Report date November 21, 2019 · Filed November 25, 2019

Jointly reported with INTERWEST PARTNERS X LP, InterWest Management Partners X, LLC, NASR KHALED, Desai Keval, Kliman Gilbert H

Section 16 reporting ended · disclosed 2019-11-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2019-11-21 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2019-11-21 · Other · Disposed 2,742,239 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share. F2: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2019-11-21 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2019-11-21 · Other · Disposed 3,005 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share. F3: The securities are directly held by InterWest Venture Management Company ("IVMC"). Gilbert H. Kliman transferred these shares to IVMC for no consideration pursuant to a contractual agreement between Kliman and IW10. Arnold L. Oronsky and Gilbert H. Kliman are owners, directors and officers of IVMC and as such may be deemed to beneficially own the shares held by IVMC. Each of Arnold L. Oronsky and Gilbert H. Kliman disclaim beneficial ownership of such shares except to the extend of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share.

F2: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

F3: The securities are directly held by InterWest Venture Management Company ("IVMC"). Gilbert H. Kliman transferred these shares to IVMC for no consideration pursuant to a contractual agreement between Kliman and IW10. Arnold L. Oronsky and Gilbert H. Kliman are owners, directors and officers of IVMC and as such may be deemed to beneficially own the shares held by IVMC. Each of Arnold L. Oronsky and Gilbert H. Kliman disclaim beneficial ownership of such shares except to the extend of his pecuniary interest therein.

Eiger BioPharmaceuticals, Inc.

Report date October 18, 2018 · Filed October 22, 2018

Jointly reported with INTERWEST PARTNERS X LP, InterWest Management Partners X, LLC, Kliman Gilbert H, Desai Keval, NASR KHALED

Section 16 reporting ended · disclosed 2018-10-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,362,327	Last balance in matching sequence After 2018-10-18 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2018-10-18 · Sale · Disposed 210,800 · Balance 1,388,792 F1: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $12.00 to $12.30 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, are Venture Members of IMP10. All Reporting Persons disclaim beneficial ownership of shares of Eiger BioPharmaceuticals, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement. Row 2 · 2018-10-18 · Sale · Disposed 26,465 · Balance 1,362,327 F2: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $12.00 to $12.03 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, are Venture Members of IMP10. All Reporting Persons disclaim beneficial ownership of shares of Eiger BioPharmaceuticals, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement.

Filing footnotes · ownership attribution and instrument terms

F1: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $12.00 to $12.30 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

F2: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $12.00 to $12.03 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

F3: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, are Venture Members of IMP10. All Reporting Persons disclaim beneficial ownership of shares of Eiger BioPharmaceuticals, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement.

TESARO, Inc.

Report date August 07, 2018 · Filed August 09, 2018

Section 16 reporting ended · disclosed 2018-08-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,479	Ending reported balance After 2018-08-07 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2018-08-07 · Exercise / conversion · Acquired 10,000 · Balance 12,479 Row 2 · 2018-08-07 · Sale · Disposed 10,000 · Balance 2,479
Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.36 · Expires 2018-08-08	Direct	0	Reported balance After 2018-08-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-08-07 · Exercise / conversion · Disposed 10,000 · Balance 0 F1: The Reporting Person ceased to be a director of the Issuer on May 10, 2018. As such all previously issued NQ Stock Options (right to buy) expired on 08/08/2018.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person ceased to be a director of the Issuer on May 10, 2018. As such all previously issued NQ Stock Options (right to buy) expired on 08/08/2018.

Venus Concept Inc.

Report date November 07, 2019 · Filed November 13, 2019

Jointly reported with InterWest Partners IX, LP, InterWest Management Partners IX, LLC, NASR KHALED

Section 16 reporting ended · disclosed 2019-11-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	658,657	Reported balance After 2019-11-07 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2019-11-07 · Conversion · Acquired 301,605 · Balance 658,657 F1: Received in connection with the Agreement and Plan of Merger and Reorganization dated March 15, 2019, among the Issuer (formerly known as Restoration Robotics, Inc.), Radiant Merger Sub Ltd, an entity organized under the laws of Israel and Venus Concept Ltd, an entity organized under the laws of Israel (the "Merger"), upon the conversion of the outstanding principal and any accrued and unpaid interest of an 8% Convertible Promissory Notes issued by Venus Concept Inc., dated as of February 28, 2019 in the original principal amount of $2,000,000.00 and accrued interest income of $110,027.40. Share data reported herein reflects the 1-for-15 reverse stock split that occurred after the note conversion on November 7, 2019. F3: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664 prior to the 1-for-15 reverse stock split that occurred on November 7, 2019. F2: The securities are directly held by InterWest Partners IX, LP ("IW9"). InterWest Management Partners IX, LLC ("IMP9") as the general partner of IW9, may be deemed to beneficially own the shares held by IW9. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP9, and Khaled A. Nasr is a Venture Member of IMP9. Gilbert H. Kliman is also a Director of the Issuer, and has filed a separate Form 4 in his own name. Each of the foregoing persons may be deemed to beneficially own the shares held by IW9, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. IW9 ceased to be a 10% owner upon closing of the Merger.
Unsecured Subordinated Convertible Promissory NoteSEC Table II · derivative / convertible security · Expires 2020-08-28	Direct	0	Reported balance After 2019-11-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-11-07 · Conversion · Disposed Not disclosed · Balance 0 F3: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664 prior to the 1-for-15 reverse stock split that occurred on November 7, 2019. F4: This Unsecured Subordinated Convertible Promissory Note converted upon the consummation of the Merger, pursuant to its terms.

Filing footnotes · ownership attribution and instrument terms

F1: Received in connection with the Agreement and Plan of Merger and Reorganization dated March 15, 2019, among the Issuer (formerly known as Restoration Robotics, Inc.), Radiant Merger Sub Ltd, an entity organized under the laws of Israel and Venus Concept Ltd, an entity organized under the laws of Israel (the "Merger"), upon the conversion of the outstanding principal and any accrued and unpaid interest of an 8% Convertible Promissory Notes issued by Venus Concept Inc., dated as of February 28, 2019 in the original principal amount of $2,000,000.00 and accrued interest income of $110,027.40. Share data reported herein reflects the 1-for-15 reverse stock split that occurred after the note conversion on November 7, 2019.

F2: The securities are directly held by InterWest Partners IX, LP ("IW9"). InterWest Management Partners IX, LLC ("IMP9") as the general partner of IW9, may be deemed to beneficially own the shares held by IW9. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP9, and Khaled A. Nasr is a Venture Member of IMP9. Gilbert H. Kliman is also a Director of the Issuer, and has filed a separate Form 4 in his own name. Each of the foregoing persons may be deemed to beneficially own the shares held by IW9, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. IW9 ceased to be a 10% owner upon closing of the Merger.

F3: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664 prior to the 1-for-15 reverse stock split that occurred on November 7, 2019.

F4: This Unsecured Subordinated Convertible Promissory Note converted upon the consummation of the Merger, pursuant to its terms.

Vyome Holdings, Inc

Report date August 06, 2019 · Filed August 08, 2019

Jointly reported with INTERWEST PARTNERS X LP, InterWest Management Partners X, LLC, Kliman Gilbert H, Desai Keval, NASR KHALED

Section 16 reporting ended · disclosed 2019-08-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	380,224	Reported balance After 2019-08-06 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2019-08-06 · Purchase · Acquired 25,000 · Balance 380,224 F1: The reporting persons purchased these shares directly from the underwriter in the Issuer's registered offering of Common Stock with 75% warrant coverage at a price of $4.00 per unit. There was no additional consideration paid for the warrants. F2: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, and are Venture Members of IMP10. Douglas Fisher, a Member of IMP10 is also a Director of the Issuer, and when required, files a separate Form 4 in his own name. All Reporting Persons disclaim beneficial ownership of shares of Obalon Therapeutics, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement.
Warrants (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 · Expires 2024-08-05	Direct	18,750	Reported balance After 2019-08-06 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-08-06 · Purchase · Acquired 18,750 · Balance 18,750 F1: The reporting persons purchased these shares directly from the underwriter in the Issuer's registered offering of Common Stock with 75% warrant coverage at a price of $4.00 per unit. There was no additional consideration paid for the warrants. F2: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, and are Venture Members of IMP10. Douglas Fisher, a Member of IMP10 is also a Director of the Issuer, and when required, files a separate Form 4 in his own name. All Reporting Persons disclaim beneficial ownership of shares of Obalon Therapeutics, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting persons purchased these shares directly from the underwriter in the Issuer's registered offering of Common Stock with 75% warrant coverage at a price of $4.00 per unit. There was no additional consideration paid for the warrants.

F2: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, and are Venture Members of IMP10. Douglas Fisher, a Member of IMP10 is also a Director of the Issuer, and when required, files a separate Form 4 in his own name. All Reporting Persons disclaim beneficial ownership of shares of Obalon Therapeutics, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 16, 2017 Filed Oct 17, 2017 22:44 UTC	Venus Concept Inc. HAIR · Entity 55304	ConversionCommon Stock	1,538,461	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-17-038922 · doc1.xml · nonDerivative · entry 1 InterWest Partners IX, LP · CIK 0001398928 · 10% owner InterWest Management Partners IX, LLC · CIK 0001398927 · 10% owner GIANOS PHILIP T · CIK 0001207831 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Holmes W Stephen · CIK 0001293923 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,538,461 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F2 · ownership.direct: The shares are directly held by InterWest Partners IX, LP ("InterWest IX"). InterWest Management Partners IX, LLC ("IMP IX"), as the general partner of InterWest IX, may be deemed to beneficially own the shares held by InterWest IX. Philip Gianos, Arnold Oronsky, Gilbert Kliman, W. Stephen Holmes and Khaled Nasr are managing directors of IMP IX, and as such may be deemed to beneficially own the shares held by InterWest IX. Each of the foregoing persons disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document
October 11, 2017 Filed Oct 13, 2017 23:01 UTC	Venus Concept Inc. HAIR · Entity 55304	OtherConvertible Promissory Note · Derivative	Not disclosed	$1,183,713.69 Strike: $7.00	$1,183,713.69	Disclosure SEC source: 0001140361-17-038669 · doc1.xml · derivative · entry 1 InterWest Partners IX, LP · CIK 0001398928 · 10% owner InterWest Management Partners IX, LLC · CIK 0001398927 · 10% owner Holmes W Stephen · CIK 0001293923 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner GIANOS PHILIP T · CIK 0001207831 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · Not disclosed shares Expires not disclosed F1 · kind: The securities were originally acquired from the Issuer on September 6, 2017; however, the conversion price was set upon the pricing of the Issuer's Initial Public Offering (the "IPO"). F2 · reported_value: The amount reported represents the principal amount of the Reporting Person's Convertible Promissory Note (the "Note") only. Accrued interest of 5% per year based on the actual number of days outstanding through the conversion date will also convert. F2 · price: The amount reported represents the principal amount of the Reporting Person's Convertible Promissory Note (the "Note") only. Accrued interest of 5% per year based on the actual number of days outstanding through the conversion date will also convert. F3 · derivative.exercise_date: The outstanding principal and accrued interest of the Note automatically converts into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the IPO upon the closing of the IPO; if not so converted, the Note has a maturity date of September 6, 2018, at which time it will automatically convert into shares of the Issuer's capital stock. F3 · derivative.expiration_date: The outstanding principal and accrued interest of the Note automatically converts into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the IPO upon the closing of the IPO; if not so converted, the Note has a maturity date of September 6, 2018, at which time it will automatically convert into shares of the Issuer's capital stock. F3 · derivative.underlying_shares: The outstanding principal and accrued interest of the Note automatically converts into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the IPO upon the closing of the IPO; if not so converted, the Note has a maturity date of September 6, 2018, at which time it will automatically convert into shares of the Issuer's capital stock. F2 · valueOwnedAfter: The amount reported represents the principal amount of the Reporting Person's Convertible Promissory Note (the "Note") only. Accrued interest of 5% per year based on the actual number of days outstanding through the conversion date will also convert. F4 · ownership.direct: The convertible promissory note is directly held by InterWest Partners IX, LP ("InterWest IX"). InterWest Management Partners IX, LLC ("IMP IX"), as the general partner of InterWest IX, may be deemed to beneficially own the shares held by InterWest IX. Philip Gianos, Arnold Oronsky, Gilbert Kliman, W. Stephen Holmes and Khaled Nasr are managing directors of IMP IX, and as such may be deemed to beneficially own the shares held by InterWest IX. Each of the foregoing persons disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document
September 27, 2017 Filed Sep 29, 2017 19:16 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	GrantDirector Stock Option (Right to Buy) · Derivative	6,000	$0.00 Strike: $6.71	$0.00	Disclosure SEC source: 0001140361-17-037014 · doc1.xml · derivative · entry 1 ORONSKY ARNOLD L · CIK 0001207833 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2027-09-26 F1 · derivative.exercise_date: The option vests over a 12 month period: 1/12th on October 27, 2017, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document
June 02, 2017 Filed Jun 2, 2017 18:01 UTC	DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930	GrantOption (Right to Buy) · Derivative	7,500	Not disclosed Strike: $5.90	Not disclosed	Disclosure SEC source: 0001209191-17-037409 · doc4.xml · derivative · entry 1 ORONSKY ARNOLD L · CIK 0001207833 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2024-06-01 F2 · price: Not applicable. F1 · derivative.exercise_date: This option vests fully on June 2, 2018, on the one year anniversary of the grant date. Read SEC document
June 01, 2017 Filed Jun 5, 2017 18:15 UTC	TESARO, Inc. TSRO · Entity 160894	GrantDirector Nonqualified Stock Option (right to buy) · Derivative	12,000	$0.00 Strike: $149.22	$0.00	Disclosure SEC source: 0001104659-17-037537 · a4.xml · derivative · entry 2 ORONSKY ARNOLD L · CIK 0001207833 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-06-01 F2 · derivative.exercise_date: The option vests on the earlier of the one-year anniversary of the date of grant and the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document
June 01, 2017 Filed Jun 5, 2017 18:15 UTC	TESARO, Inc. TSRO · Entity 160894	GrantCommon Stock	335	$0.00	$0.00	Disclosure SEC source: 0001104659-17-037537 · a4.xml · nonDerivative · entry 1 ORONSKY ARNOLD L · CIK 0001207833 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By corporation Disclosed balance after: 1,338 F1 · shares: The Reporting Person has elected to receive common stock in lieu of cash for board retainers and fees otherwise payable in cash. F3 · ownership.nature: The shares are beneficially owned by InterWest Venture Management Company ("IVMC"). The Reporting Person is an officer and director of IVMC and may be deemed to own beneficially the shares held by IVMC. Read SEC document
April 24, 2017 Filed Apr 26, 2017 13:07 UTC	APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949	OtherWarrant to buy Common · Derivative	91	$0.00 Strike: $4.54	$0.00	Disclosure SEC source: 0000899243-17-010898 · doc4.xml · derivative · entry 6 ORONSKY ARNOLD L · CIK 0001207833 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Partnership Disclosed balance after: 0 Underlying: Common · 91 shares Expires 2017-05-02 F6 · ownership.nature: Shares are owned by II8. The General Partner of IW8 is IMP8. The Reporting Person is a Managing Director of IMP8, shares voting and investment power with the other Managing Directors of IMP8, and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document
April 24, 2017 Filed Apr 26, 2017 13:07 UTC	APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949	OtherWarrant to buy Common · Derivative	328	$0.00 Strike: $4.54	$0.00	Disclosure SEC source: 0000899243-17-010898 · doc4.xml · derivative · entry 5 ORONSKY ARNOLD L · CIK 0001207833 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Partnership Disclosed balance after: 0 Underlying: Common · 328 shares Expires 2017-05-02 F5 · ownership.nature: Shares are owned by IIQ8. The General Partner of IW8 is IMP8. The Reporting Person is a Managing Director of IMP8, shares voting and investment power with the other Managing Directors of IMP8, and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document
April 24, 2017 Filed Apr 26, 2017 13:07 UTC	APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949	OtherWarrant to buy Common · Derivative	11,476	$0.00 Strike: $4.54	$0.00	Disclosure SEC source: 0000899243-17-010898 · doc4.xml · derivative · entry 4 ORONSKY ARNOLD L · CIK 0001207833 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Partnership Disclosed balance after: 0 Underlying: Common · 11,476 shares Expires 2017-05-02 F4 · ownership.nature: Shares are owned by IW8. The General Partner of IW8 is InterWest Management Partners VIII, LLC ("IMP8"). The Reporting Person is a Managing Director of IMP8, shares voting and investment power with the other Managing Directors of IMP8, and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document
April 24, 2017 Filed Apr 26, 2017 13:07 UTC	APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949	OtherCommon	28	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-010898 · doc4.xml · nonDerivative · entry 3 ORONSKY ARNOLD L · CIK 0001207833 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Partnership Disclosed balance after: 11,208 F3 · price: Represents cashless exercise of a warrant by InterWest Investors VIII, LP ("II8"). 63 shares of common stock were withheld by the issuer at the market price of $6.58 per share to fund the cashless exercise of 91 warrants. F6 · ownership.nature: Shares are owned by II8. The General Partner of IW8 is IMP8. The Reporting Person is a Managing Director of IMP8, shares voting and investment power with the other Managing Directors of IMP8, and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document
April 24, 2017 Filed Apr 26, 2017 13:07 UTC	APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949	OtherCommon	101	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-010898 · doc4.xml · nonDerivative · entry 2 ORONSKY ARNOLD L · CIK 0001207833 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Partnership Disclosed balance after: 40,181 F2 · price: Represents cashless exercise of a warrant by InterWest Investors Q VIII, LP ("IIQ8"). 227 shares of common stock were withheld by the issuer at the market price of $6.58 per share to fund the cashless exercise of 328 warrants. F5 · ownership.nature: Shares are owned by IIQ8. The General Partner of IW8 is IMP8. The Reporting Person is a Managing Director of IMP8, shares voting and investment power with the other Managing Directors of IMP8, and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document
April 24, 2017 Filed Apr 26, 2017 13:07 UTC	APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949	OtherCommon	3,559	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-010898 · doc4.xml · nonDerivative · entry 1 ORONSKY ARNOLD L · CIK 0001207833 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Partnership Disclosed balance after: 1,404,515 F1 · price: Represents cashless exercise of a warrant by InterWest Partners VIII, LP ("IW8"). 7,917 shares of common stock were withheld by the issuer at the market price of $6.58 per share to fund the cashless exercise of 11,476 warrants. F4 · ownership.nature: Shares are owned by IW8. The General Partner of IW8 is InterWest Management Partners VIII, LLC ("IMP8"). The Reporting Person is a Managing Director of IMP8, shares voting and investment power with the other Managing Directors of IMP8, and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document
March 23, 2017 Filed Mar 27, 2017 19:07 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	GrantDirector Stock Option (Right to Buy) · Derivative	12,000	$0.00 Strike: $7.88	$0.00	Disclosure SEC source: 0001140361-17-013499 · doc1.xml · derivative · entry 1 ORONSKY ARNOLD L · CIK 0001207833 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-03-22 F1 · derivative.exercise_date: The option vests over a 3 year period: 1/36th on December 21, 2016 after which 1/36th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document
February 28, 2017 Filed Mar 2, 2017 19:25 UTC	APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949	GrantStock Option (right to buy) · Derivative	8,000	$0.00 Strike: $7.75	$0.00	Disclosure SEC source: 0000899243-17-006170 · doc4.xml · derivative · entry 1 ORONSKY ARNOLD L · CIK 0001207833 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2027-02-28 F1 · derivative.exercise_date: Option becomes exercisable on February 28, 2018. Read SEC document
October 12, 2016 Filed Oct 12, 2016 17:34 UTC	Vyome Holdings, Inc OBLN · Entity 1824	ConversionSeries E Preferred Stock · Derivative	373,803	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-16-145722 · doc4.xml · derivative · entry 6 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner GIANOS PHILIP T · CIK 0001207831 · 10% owner Holmes W Stephen · CIK 0001293923 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 373,803 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the issuer's Series E Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · price: Each share of the issuer's Series E Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.exercise_date: Each share of the issuer's Series E Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.expiration_date: Each share of the issuer's Series E Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.direct: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10. Philip T. Gianos, W. Stephen Holmes, Gilbert H. Kliman and Arnold L. Oronsky are the managing directors of IMP10, and Keval Desai and Khalad A. Nasr are venture members of IMP10. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. The reporting persons have designated a representative, currently Doug Fisher, a consultant of InterWest Venture Management Co., to serve on the issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. Read SEC document
October 12, 2016 Filed Oct 12, 2016 17:34 UTC	Vyome Holdings, Inc OBLN · Entity 1824	ConversionSeries D Preferred Stock · Derivative	464,494	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-16-145722 · doc4.xml · derivative · entry 5 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner GIANOS PHILIP T · CIK 0001207831 · 10% owner Holmes W Stephen · CIK 0001293923 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 464,494 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of the issuer's Series D Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · price: Each share of the issuer's Series D Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.exercise_date: Each share of the issuer's Series D Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.expiration_date: Each share of the issuer's Series D Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.direct: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10. Philip T. Gianos, W. Stephen Holmes, Gilbert H. Kliman and Arnold L. Oronsky are the managing directors of IMP10, and Keval Desai and Khalad A. Nasr are venture members of IMP10. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. The reporting persons have designated a representative, currently Doug Fisher, a consultant of InterWest Venture Management Co., to serve on the issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. Read SEC document
October 12, 2016 Filed Oct 12, 2016 17:34 UTC	Vyome Holdings, Inc OBLN · Entity 1824	ConversionSeries C Preferred Stock · Derivative	1,615,041	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-16-145722 · doc4.xml · derivative · entry 4 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner GIANOS PHILIP T · CIK 0001207831 · 10% owner Holmes W Stephen · CIK 0001293923 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,615,041 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-213551) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · price: Each share of the issuer's Series C Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-213551) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-213551) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-213551) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.direct: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10. Philip T. Gianos, W. Stephen Holmes, Gilbert H. Kliman and Arnold L. Oronsky are the managing directors of IMP10, and Keval Desai and Khalad A. Nasr are venture members of IMP10. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. The reporting persons have designated a representative, currently Doug Fisher, a consultant of InterWest Venture Management Co., to serve on the issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. Read SEC document
October 12, 2016 Filed Oct 12, 2016 17:34 UTC	Vyome Holdings, Inc OBLN · Entity 1824	ConversionCommon Stock	373,803	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-16-145722 · doc4.xml · nonDerivative · entry 3 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner GIANOS PHILIP T · CIK 0001207831 · 10% owner Holmes W Stephen · CIK 0001293923 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,453,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of the issuer's Series E Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.direct: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10. Philip T. Gianos, W. Stephen Holmes, Gilbert H. Kliman and Arnold L. Oronsky are the managing directors of IMP10, and Keval Desai and Khalad A. Nasr are venture members of IMP10. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. The reporting persons have designated a representative, currently Doug Fisher, a consultant of InterWest Venture Management Co., to serve on the issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. Read SEC document
October 12, 2016 Filed Oct 12, 2016 17:34 UTC	Vyome Holdings, Inc OBLN · Entity 1824	ConversionCommon Stock	464,494	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-16-145722 · doc4.xml · nonDerivative · entry 2 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner GIANOS PHILIP T · CIK 0001207831 · 10% owner Holmes W Stephen · CIK 0001293923 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,079,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of the issuer's Series D Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.direct: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10. Philip T. Gianos, W. Stephen Holmes, Gilbert H. Kliman and Arnold L. Oronsky are the managing directors of IMP10, and Keval Desai and Khalad A. Nasr are venture members of IMP10. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. The reporting persons have designated a representative, currently Doug Fisher, a consultant of InterWest Venture Management Co., to serve on the issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. Read SEC document
October 12, 2016 Filed Oct 12, 2016 17:34 UTC	Vyome Holdings, Inc OBLN · Entity 1824	ConversionCommon Stock	1,615,041	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-16-145722 · doc4.xml · nonDerivative · entry 1 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner GIANOS PHILIP T · CIK 0001207831 · 10% owner Holmes W Stephen · CIK 0001293923 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,615,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the issuer's Series C Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-213551) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.direct: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10. Philip T. Gianos, W. Stephen Holmes, Gilbert H. Kliman and Arnold L. Oronsky are the managing directors of IMP10, and Keval Desai and Khalad A. Nasr are venture members of IMP10. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. The reporting persons have designated a representative, currently Doug Fisher, a consultant of InterWest Venture Management Co., to serve on the issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.